Elekta (OTCMKTS:EKTAY) vs. Anteris Technologies Global (NASDAQ:AVR) Head-To-Head Comparison

Elekta (OTCMKTS:EKTAY) and Anteris Technologies Global (NASDAQ:AVR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Profitability

This table compares Elekta and Anteris Technologies Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elekta	1.62%	12.14%	3.79%
Anteris Technologies Global	-3,944.93%	-252.71%	-169.61%

Valuation & Earnings

This table compares Elekta and Anteris Technologies Global”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elekta	$1.71 billion	1.33	$22.37 million	$0.07	87.81
Anteris Technologies Global	$2.70 million	87.13	-$76.29 million	($1.81)	-3.15

Elekta has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than Elekta, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Elekta and Anteris Technologies Global, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elekta	1	2	0	0	1.67
Anteris Technologies Global	1	0	1	0	2.00

Anteris Technologies Global has a consensus target price of $15.00, suggesting a potential upside of 162.70%. Given Anteris Technologies Global’s stronger consensus rating and higher probable upside, analysts clearly believe Anteris Technologies Global is more favorable than Elekta.

Risk & Volatility

Elekta has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Anteris Technologies Global has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.

Summary

Elekta beats Anteris Technologies Global on 7 of the 12 factors compared between the two stocks.

About Elekta

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.